New targeted drug joins fight against advanced lung cancer
NCT ID NCT06930794
Summary
This study is testing whether adding a new oral drug called vebreltinib to standard chemotherapy works better than chemotherapy alone for a specific type of advanced lung cancer. It is for adults with a certain genetic marker (MET-positive) who have not yet received any treatment for their advanced disease. The main goal is to see if the combination can better control the cancer and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.